Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 1059 • 2016 ACR/ARHP Annual Meeting
Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy
Gabriela Hernandez-Molina¹, Itzel Gonzalez-Pérez², Carlos Pacheco² and Antonio R. Cabral³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Few studies have reported impaired health related quality of life (HRQoL) in patients with primary antiphospholipid syndrome (APS); however the causes of this outcome…
Abstract Number: 1060 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports
Noha Abdel-Wahab¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: A systematic review of case reports to summarize existing evidence in the literature regarding the association of APS and infection during childhood. Our aims…
Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…
Abstract Number: 1068 • 2016 ACR/ARHP Annual Meeting
Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years
Gabriela Medina¹, Eduardo Briones-Garcia², Pilar Cruz-Dominguez³, Oscar I Florez-Durante⁴, Olga-Lidia Vera-Lastra⁵, Miguel A. Saavedra⁶ and Luis J. Jara⁷, ¹Clinical research unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ²Direction of Education and Research, Clinical Research Unit, Mexico, Mexico, ³Research Division, Hospital de Especialidades, Centro Médico La Raza, IMSS, Mexico, Mexico, ⁴Clinical researh Unit, Escuela Nacional de Ciencias Biológicas Instituto Politécnico Nacional, Mexico, Mexico, ⁵Rheumatology, Inst Mexicano Seguro Social, Mexico City, Mexico, ⁶Rheumatology, Centro Médico Nacional La Raza IMSS, México, Mexico, ⁷Direction of education and research, Hospital de Especialidades Centro Medico La Raza, Mexico City, Mexico
Background/Purpose: In some antiphospholipid syndrome (APS) patients, the antiphospholipid antibodies (aPL) becomes persistently negative. Discontinuation of anticoagulation has been proposed, however the long term follow-up…
Abstract Number: 1071 • 2016 ACR/ARHP Annual Meeting
Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations
Diego Hernández-Ramírez¹, Gabriela Hernandez-Molina², Carlos Núñez-Álvarez³, Miguel Astudillo-Angel⁴, Carlos Pacheco¹, Elizabeth Olivares-Martínez¹ and Antonio R. Cabral⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Thrombocytopenia and hemolytic anemia (HA) are considered non-criteria clinical manifestations by the Sydney revised criteria for APS. These features can precede, follow a thrombotic…
Abstract Number: 1072 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Ozan Unlu¹, Doruk Erkan², Maria Tektonidou³ and On Behalf of APS ACTION .⁴, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁴., New York, NY
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors increase the risk of thrombotic clinical manifestations in antiphospholipid antibody (aPL)-positive patients. The prevalence of CVD risk factors…
Abstract Number: 1962 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target
Jason S Knight¹, Patrick S. Coit¹, He Meng¹, Srilakshmi Yalavarthi¹, Paul Renauer¹, Robert C Grenn¹, Levi F Mazza¹, Hui Wang², Daniel T Eitzman² and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment of the thrombotic manifestations of antiphospholipid syndrome (APS) primarily focuses on inhibiting clotting pathways. In an effort to identify upstream inflammatory targets that…
Abstract Number: 1965 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up
Ozan Unlu¹, W. David Branch², Paul R. Fortin³, Maria Gerosa⁴, Guillermo J. Pons-Estel⁵, Maria Tektonidou⁶, Amaia Ugarte⁷, Doruk Erkan⁸ and On Behalf of APS ACTION .⁹, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ³Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁶First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁷Hospital Universitario Cruces, Biscay, Spain, ⁸Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁹., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients. Previously, based on…
Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Francesca Dall'Ara¹, Mara Taraborelli², Rossella Reggia¹, Micaela Fredi², Maria Gerosa³, Laura Massaro⁴, Ariela Hoxha⁵, Marta Tonello⁵, Patrice Cacoub⁶, Nathalie Costedoat-Chalumeau⁷, Franco Franceschini², Pier Luigi Meroni⁸, Jean Charles Piette⁶, Amelia Ruffatti⁵, Guido Valesini⁴ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁴Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁸Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy
Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…
Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting
in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Francisco Velasco², Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui³, Eduardo Collantes-Estevez¹, Lucia Fernandez-del Rio⁴, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁴, Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, ⁴Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…
Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Cécile Yelnik^1,2, Elodie Drumez³, Sylvain Dubucquoi^2,4,5, Vincent Sobanski^1,2,4, Hélène Maillard^1,6, Alain Duhamel³, David Launay^1,2,4, Eric Hachulla^1,2,4, Pierre-Yves Hatron^1,2 and Marc Lambert^1,2,4, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³CERIM, Université Lille Nord de France, Lille, France, ⁴LIRIC, INSERM UMR 995, Lille, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Krishan Gupta¹, Manish Rathi², Navin Pattanashetti³, Ritambhra Nada⁴ and Aman Sharma⁵, ¹Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Junior Resident, Chandigarh, India, ⁴Histopathology, Professor, Chandigarh, India, ⁵Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…
Abstract Number: 1854 • 2015 ACR/ARHP Annual Meeting
Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Eduardo Collantes-Estevez¹, Mª Jose Cuadrado², Rocio Gonzalez-Conejero³, Constantino Martinez³ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: 1) To identify and characterize miRNAs related to the pathogenesis of CVD in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) patients; 2) To…
Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Nayef M. Kazzaz¹, Patrick S. Coit², Emily E. Lewis³, W Joseph McCune⁴, Amr H. Sawalha² and Jason S. Knight², ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
Abstract Number: 2000 • 2015 ACR/ARHP Annual Meeting
Immune Response Against Â Î²2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome
Pier Luigi Meroni^1,2, Marisa Benagiano³, Maria Gerosa⁴, Jacopo Romagnoli⁵, Michael Mahler⁶, Maria Orietta Borghi^7,8, Alessia Grassi⁹, Chiara Della Bella³, Giacomo Emmi³, Amedeo Amedei^3,10, Elena Silvestri³, Lorenzo Emmi¹¹, Domenico Prisco^9,10 and Mario Milco D'Elios^3,10, ¹Clinical Sciences and Community Heath, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy, ³Department of Experimental and Clinical Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁵Department of Surgery, Department of Surgery, Catholic University of Rome, Rome, Italy, ⁶Inova Diagnostics, San Diego, CA, ⁷Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁸Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁹Department of Experimental and Clinical Medicine,, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁰Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy, ¹¹Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of arterial and venous thrombosis, and by recurrent abortions, in patients with persistent presence of autoantibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].